BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 31454045)

  • 1. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
    Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
    JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of high-dose
    Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
    J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
    Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
    Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
    Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
    Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
    Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
    Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
    Berthold F; Faldum A; Ernst A; Boos J; Dilloo D; Eggert A; Fischer M; Frühwald M; Henze G; Klingebiel T; Kratz C; Kremens B; Krug B; Leuschner I; Schmidt M; Schmidt R; Schumacher-Kuckelkorn R; von Schweinitz D; Schilling FH; Theissen J; Volland R; Hero B; Simon T
    Ann Oncol; 2020 Mar; 31(3):422-429. PubMed ID: 32067684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
    Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
    Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
    Streby KA; Parisi MT; Shulkin BL; LaBarre B; Bagatell R; Diller L; Grupp SA; Matthay KK; Voss SD; Yu AL; London WB; Park JR; Yanik GA; Naranjo A
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30418. PubMed ID: 37199022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
    Choi JY; Kang HJ; Hong KT; Hong CR; Lee YJ; Park JD; Phi JH; Kim SK; Wang KC; Kim IH; Park SH; Choi YH; Cheon JE; Park KD; Shin HY
    Int J Clin Oncol; 2019 Dec; 24(12):1515-1525. PubMed ID: 31352632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
    Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
    Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
    Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
    Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
    Zage PE; Kletzel M; Murray K; Marcus R; Castleberry R; Zhang Y; London WB; Kretschmar C;
    Pediatr Blood Cancer; 2008 Dec; 51(6):747-53. PubMed ID: 18704922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
    Sung KW; Lim DH; Son MH; Lee SH; Yoo KH; Koo HH; Kim JH; Suh YL; Joung YS; Shin HJ
    Neuro Oncol; 2013 Mar; 15(3):352-9. PubMed ID: 23258845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
    Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
    Matthay KK; Villablanca JG; Seeger RC; Stram DO; Harris RE; Ramsay NK; Swift P; Shimada H; Black CT; Brodeur GM; Gerbing RB; Reynolds CP
    N Engl J Med; 1999 Oct; 341(16):1165-73. PubMed ID: 10519894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma.
    Qayed M; Chiang KY; Ricketts R; Alazraki A; Tahvildari A; Haight A; George B; Esiashvili N; Katzenstein HM
    Pediatr Blood Cancer; 2012 Mar; 58(3):448-52. PubMed ID: 21538822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.